CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Pancreatic Enzymedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03097029
NCT03097029Phase 2Completed
CompareCT.gov

Use of Pancreatic Enzymes in Short Bowel Syndrome

Children's Hospital of Philadelphia·interventional·Posted Mar 31, 2017·Updated Mar 20, 2020

In Brief

A Phase 2 clinical trial evaluating Pancreatic Enzyme for Short Bowel Syndrome. Completed, enrolled 16 participants across 1 site.

Detailed Summary

Patients with short bowel syndrome have a high mortality rate that is mainly attributed to complications from central lines and long-term intravenous (IV) nutrition. There are few medical therapies to date that improve gut absorption in patients with short bowel syndrome. The primary objective of this study is to evaluate if absorption from the GI tract improves in subjects with short bowel syndrome following therapy with pancreatic enzymes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsShort Bowel Syndrome
CountriesUnited States
CollaboratorsAbbVie

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedMar 31, 2017
Enrollment StartMar 24, 2017
Primary CompletionFeb 1, 2019
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.3 years ago

Interventions

Pancreatic Enzymedrug

All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.